65,437 trials
Hypertension
Primary: Percentage of Patients With Controlled Blood Pressure — 46.1; 24.1 Percentage of patients — p=<0.0001
Back Pain Without Radiation
Primary: Change From Baseline to Week 13 in Brief Pain Inventory (BPI), 24-hour Average Pain Scores — -2.32; -1.50 units on a scale — p=0.004
Neuropathic Pain
Primary: Number and Severity of Adverse Events (All Causalities); Baseline to Final Visit (Week 4) — 1; 1; 3; 1 participants
Osteoarthritis · Arthritis, Rheumatoid
Primary: Mean Change in Medical Outcomes Study 12-item Short-Form Health Survey, Version 2 Score From Baseline to Final Visit. — 11.2 Units on a scale
Breast Cancer
Primary: Overall Tumor Response — 6; 0; 1; 26 participants
Gastroesophageal Reflux Disease · GERD · Heartburn
Primary: Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R) Success — 27; 32; 31 participants — p=0.528
Schizophrenia
Primary: Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I) — 13; 30; 10; 20 participants
Hypercholesterolemia
Primary: Mean Percent Change of Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline After 8 Weeks. — -49.29; -38.05 Percent of Baseline Value — p=<0.0001
Restless Legs Syndrome
Primary: Change From Baseline in International Restless Legs Syndrome Study Group Rating Scale (IRLS) Total Score After 26 Weeks — -13.7; -11.1 Scores on a scale — p=0.0077
Crohn's Disease
Primary: Response Status With Response Defined as at Least 100 Point Decrease in Crohn's Disease Activity Score (CDAI Score) From Baseline in the Induction Phase — 334; 205…
Hepatitis B
Primary: Number of Subjects Seropositive for Anti-hepatitis B Surface Antigen (Anti-HBs) Antibodies — 0; 22; 2; 21 subjects
Healthy
Primary: Area Under the Plasma Drug Concentration-time Curve From Time 0 to Infinity (AUC) — 1308; 1326 microgram *day/mL
Asthma
Primary: Change in Mean Weekly Morning Peak Expiratory Flow From Baseline to the End of the Trial — -3.93; -3.15; -24.63 L/min
Seasonal Allergic Rhinitis
Primary: Mean 24-hour Reflective Total 5 Symptoms Score (T5SS) Over the Total Treatment Period (14 Days) — 8.68; 7.87 points on a scale — p=<0.001
Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC — 45.04; 28.66; 46.34; 29.97 ng/ml